Science Group (SAG) H2 2025 TU earnings summary

Executive summary

• Achieved record adjusted operating profit for FY25, exceeding Board expectations despite volatile market conditions, with strong recovery in the Medical sector during H2.

• Reported profit before tax and EPS will be substantially higher year-over-year, driven by investment gains from H1 corporate activity.

Financial highlights

• Gross cash at year-end 2025 was £72.6 million and net funds £61.2 million, up from £38.6 million and £26.8 million at December 2024.

• Returned £14.3 million to shareholders in 2025 via share buybacks (£10.7 million) and dividends (£3.6 million).

• High cash conversion of adjusted operating profit maintained.

Outlook and guidance

• Board anticipates continuing the share buyback programme in 2026 at a similar level to 2025, subject to market conditions and corporate activity.

• Audited FY25 results expected in late March or mid-April 2026.